迪瑞医疗: 2025年半年度报告摘要

Core Viewpoint - The report indicates a significant decline in the company's financial performance for the first half of 2025, with a notable drop in revenue and net profit compared to the same period last year [2][3]. Financial Performance - The company's operating revenue for the reporting period was approximately ¥350.69 million, representing a decrease of 60.07% compared to ¥878.27 million in the same period last year [2]. - The net profit attributable to shareholders was a loss of approximately ¥28.31 million, a decline of 117.13% from a profit of ¥165.24 million in the previous year [2]. - The net profit after deducting non-recurring gains and losses was approximately -¥31.91 million, down 119.65% from ¥162.36 million in the previous year [2]. - The net cash flow from operating activities was approximately -¥8.43 million, showing an improvement of 97.07% compared to -¥287.72 million in the previous year [2]. - Basic and diluted earnings per share were both -¥0.1038, a decrease of 117.13% from ¥0.6060 in the previous year [2]. - The weighted average return on net assets was -9.28%, down from 7.88% in the previous year [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately ¥2.96 billion, a decrease of 4.71% from ¥3.11 billion at the end of the previous year [2]. - The net assets attributable to shareholders were approximately ¥1.96 billion, down 4.51% from ¥2.05 billion at the end of the previous year [3]. Shareholder Information - The largest shareholder, Shenzhen Huadexin Run Equity Investment Co., Ltd., holds 28.34% of the shares, with a total of 77,288,400 shares [3]. - Other significant shareholders include Guangdong Hengjian International Investment Co., Ltd. with 12.15% and individual shareholders such as Song Jie and Yi Xiangping with 5.40% and 3.21% respectively [3][4]. - The report notes that there have been no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - Several directors, including Song Qing, Qin Feng, Wang Xueming, and Lin Maoliang, have resigned from their positions, and new non-independent directors have been elected [4]. - Sun Bin has been appointed as the vice general manager of the company [4].